Continuous glucose monitor data on semaglutide — my results so far

hans_munich said:

Steady state is the thing most people miss.

That reframing is the part I needed. Sending this to two other people who asked me the same thing last week.

From the other side of the consultation, briefly.

hyun_seoul said:

...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

lisa_labSD said:

The mechanism that matters here is not stomach emptying, it is central.

This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

The figures, for anyone assembling their own picture. Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Carry on.